Psoriatic Disease

Clearly defining treatment targets and communicating those targets to patients is essential to optimizing outcomes in psoriatic arthritis, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.

The National Psoriasis Foundation COVID-19 Task Force is recommending booster doses of mRNA COVID-19 vaccines for some patients with psoriatic disease.

Patients with psoriasis who received biologic drugs demonstrated a lower risk — that was statistically and clinically significant — for developing psoriatic arthritis, according to data published in Arthritis & Rheumatology.

Psoriasis is “mostly mild” in patients with psoriatic arthritis yet still impacts quality of life when measured using a dermatology-specific questionnaire, according to data published in Rheumatology.

In this issue of Healio Psoriatic Disease, we focus on shared dermatology-rheumatology clinics and how they aim to advance the treatment of psoriasis and psoriatic arthritis.

Psoriatic disease management needs input from both rheumatologists and dermatologists, and a growing number of practitioners have begun to combine clinics or collaborate efforts with their fellow specialists.

In this issue of Healio Psoriatic Disease, we focus on the advent of combined dermatology-rheumatology clinics for the management of patients with psoriatic disease.

A broader array of therapies is allowing clinicians to target specific disease domains in psoriatic arthritis, but the treat-to-target “sweet spot” remains unclear, noted a presenter at the 2021 Congress of Clinical Rheumatology-East.

Both men and women of reproductive age with psoriatic arthritis who are hoping to be parents should consult their medical team and adhere to medications, according to a speaker at the 2021 Rheumatology Nurses Society annual conference.

The use of biological disease-modifying antirheumatic drugs in patients with psoriasis reduces the risk for psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.